Solid Biosciences announced it will present its largest scientific program yet at the 29th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) in May 2026, featuring 5 oral presentations and 11 posters. The presentations cover clinical development, delivery technologies, and manufacturing advances for gene therapies targeting rare neuromuscular and cardiac diseases like Duchenne muscular dystrophy and Friedreich’s ataxia. This reflects Solid's growing leadership in precision genetic medicine and progress across discovery, development, and clinical translation. The event will showcase updates on key programs and innovative delivery platforms, signaling potential advancements in treatment options for patients with devastating rare diseases.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Ethereum rose 3.17% to $1,923.53, outperforming Bitcoin's modest 0.18% gain to $64,588.87, signaling an early rotation toward large-cap altcoins. Despite this, overall market activity slowed, with declines in DeFi, stablecoin, and derivatives trading...
Gabriel Holding A/S has agreed to sell its European FurnMaster furniture manufacturing operations, including subsidiaries in Poland and Lithuania, to Leggett & Platt for an initial price of approximately EUR 9 million, with a possible additional paym...
A Gaza resident raised over £55,000 on GoFundMe to support his family but faced issues as the platform cannot pay directly to Gaza, forcing funds through intermediaries who failed to deliver the full amount. This highlights a broader problem in human...
Crypto investigator ZachXBT criticized all current hardware wallets as insecure and unreliable for signing transactions or storing significant funds. He highlighted Ledger as particularly problematic due to frequent updates that disrupt basic functio...
